We only have this paper's title and publication details.
Read it at the sourceAnswers are grounded in this paper and cite their sources.
Multicenter analysis demonstrates safety of satralizumab for neuromyelitis optica spectrum disorder in Japan, suggesting effective long-term outcomes.
Umin000050027.
No takes yet. Share an insight, caveat, or question.
Fujihara et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: